January 5, 2022
PA-21-259 - PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
PA-21-260- PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
PA-21-261 - PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
PA-21-262 - PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
Office of The Director, National Institutes of Health (OD)
The purpose of this notice is to update information regarding the total funding support normally allowed for Phase I and Phase II Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications.
Section II. Award Information
Currently Reads:
Award Budget
Total funding support (direct costs, indirect costs, fee) normally may not exceed $259,613 for Phase I awards and $1,730,751 for Phase II awards. For specific topics, NIH may exceed these total award amounts. The current list of approved topics can be found at https://sbir.nih.gov/sites/default/files/NIH_Topics_for_Budget_Waivers.pdf.
Each participating component may also set their own budget limit (higher or lower than the above) in the “Budget Guidance” of their respective topics section in the current PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for the NIH, CDC and FDA. Applicants are strongly encouraged to contact program officials prior to submitting any application in excess of the total award amounts listed above and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Phase IIB budgets must be submitted in accordance with participating IC-specific budget limitations described in the current PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for the NIH, CDC and FDA.
Revised to Read (changes shown in italics):
Award Budget
Total funding support (direct costs, indirect costs, fee) normally may not exceed $275,766 for Phase I awards and $1,838,436 for Phase II awards. For specific topics, NIH may exceed these total award amounts. The current list of approved topics can be found at https://sbir.nih.gov/sites/default/files/NIH_Topics_for_Budget_Waivers.pdf.
Each participating component may also set their own budget limit (higher or lower than the above) in the “Budget Guidance” of their respective topics section in the current PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for the NIH, CDC and FDA. Applicants are strongly encouraged to contact program officials prior to submitting any application in excess of the total award amounts listed above and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Phase IIB budgets must be submitted in accordance with participating IC-specific budget limitations described in the current PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for the NIH, CDC and FDA.
All other aspects of this FOA remain the same.
Stephanie Fertig, MBA| HHS Small Business Program Lead
SEED (Small business Education and Entrepreneurial Development)
Office of Extramural Research
and Human Services (HHS)
